

# Antimalarial Market Intelligence in Laos PDR: ACTwatch Findings 2015

**2005:** AL first-line becomes 1<sup>st</sup> line treatment; testing/treatment free in public sector

**2007:** MoH bans artemisinin monotherapies

**2008:** Public Private Mix (PPM) program launches

**2010:** G6PD testing require with prescription of Primaquine

**2013:** Artemisinin Resistance detected in Champasack Province


**2014:** PPM expands to 22 districts

**2014:** Artemisinin Resistance detected in Attapeu Province

**2015:** MoH Develops & commits to Malaria Elimination Strategy for Laos PDR


**7,586 OUTLETS SCREENED; 630 = N. of ANTIMALARIAL-STOCKING OUTLETS**

**Availability of any national first line treatment or chloroquine:** Most public sector antimalarial-stocking outlets had the first-line treatment in stock.



**Market composition:** 65% of the market composition comprised of public health facilities & community health workers (CHW).

- Public Health Facility
- CHW
- Health Facility
- Pharmacy
- Drug Store
- General Retailer
- Itinerant Drug Vendor



**1**

*Package of oral artemisinin monotherapy was found.*

**Malaria diagnostic testing is available in:**

**80** Percent of the Public Sector

**40** Percent of the Private Sector

**CHLOROQUINE INSIGHTS**

**MARAQUINE**

Each tablet contains:  
Chloroquine phosphate B.P.  
**250mg**  
**ANTIMALARIAL**

ເປັນຢາປ້ອງກັນ ແລະ ຍິນຍົວພະຍາດ ໂຂນາເລເຣຍ

**4 tablets**

- Most popular brand of CQ
- Locally manufactured
- Affordable (\$0.62)
- Brand recognition

**Antimalarial market share:** The public sector almost exclusively distributed ACT. Chloroquine dominates the private sector market.

